Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) have received an average recommendation of “Hold” from the seven analysts that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $46.75.
A number of equities analysts have issued reports on FPRX shares. BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, March 17th. Zacks Investment Research lowered Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, April 2nd. Nomura decreased their price target on Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, February 28th. Finally, BMO Capital Markets decreased their price target on Five Prime Therapeutics from $75.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 28th.
FPRX stock traded down $0.47 on Wednesday, reaching $16.88. The company’s stock had a trading volume of 191,945 shares, compared to its average volume of 547,441. Five Prime Therapeutics has a 52 week low of $15.66 and a 52 week high of $48.87. The firm has a market capitalization of $599.08, a price-to-earnings ratio of -3.14 and a beta of 3.42.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.25. The firm had revenue of $13.22 million during the quarter, compared to analyst estimates of $9.86 million. Five Prime Therapeutics had a negative return on equity of 48.79% and a negative net margin of 380.23%. sell-side analysts forecast that Five Prime Therapeutics will post -4.98 EPS for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas bought a new stake in shares of Five Prime Therapeutics during the 4th quarter worth $221,000. MetLife Investment Advisors LLC bought a new stake in shares of Five Prime Therapeutics during the 4th quarter worth $294,000. Virtus Fund Advisers LLC bought a new stake in shares of Five Prime Therapeutics during the 4th quarter worth $381,000. Fox Run Management L.L.C. bought a new stake in shares of Five Prime Therapeutics during the 4th quarter worth $386,000. Finally, Franklin Street Advisors Inc. NC bought a new stake in shares of Five Prime Therapeutics during the 4th quarter worth $548,000. 74.34% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Five Prime Therapeutics Inc (FPRX) Receives Average Recommendation of “Hold” from Analysts” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/04/18/five-prime-therapeutics-inc-fprx-receives-average-recommendation-of-hold-from-analysts.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.